1.77
-0.08(-4.32%)
Currency In USD
| Previous Close | 1.85 |
| Open | 1.81 |
| Day High | 1.85 |
| Day Low | 1.77 |
| 52-Week High | 2.64 |
| 52-Week Low | 0.53 |
| Volume | 1.84M |
| Average Volume | 5.08M |
| Market Cap | 263.74M |
| PE | -0.86 |
| EPS | -2.07 |
| Moving Average 50 Days | 1.84 |
| Moving Average 200 Days | 1.33 |
| Change | -0.08 |
If you invested $1000 in Palisade Bio, Inc. (PALI) 10 years ago, it would be worth $0 as of February 28, 2026 at a share price of $1.77. Whereas If you bought $1000 worth of Palisade Bio, Inc. (PALI) shares 4 years ago, it would be worth $0.27 as of February 28, 2026 at a share price of $1.77.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026
GlobeNewswire Inc.
Feb 23, 2026 1:40 PM GMT
Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven days Encouraging safety profile across 89 subjects supports differentiat
Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory Board
GlobeNewswire Inc.
Feb 17, 2026 1:45 PM GMT
Appointment strengthens Phase 2 development strategy for PALI-2108 in ulcerative colitis and fibrostenotic Crohn’s disease; Phase 2 ulcerative colitis IND submission planned for first half of 2026 Carlsbad, CA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pal
Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium
GlobeNewswire Inc.
Feb 09, 2026 2:00 PM GMT
Virtual fireside chat scheduled for Thursday, February 12, 2026, from 1:30 PM to 1:55 PM ET Access the webcast here Carlsbad, CA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage bi